North America Asthma and COPD Drugs Key Players-Business, Deal & Patent Strategies

Who are the Market Top Companies and What are Their Offerings?

What are the Major Recent Developments in the Market?

• In May 2026, to discover a new approach to reduce COPD flare-ups, the COPD-OMA trial was launched by the American Lung Association (ALA). Omalizumab (Xolair), an already FDA-approved drug for asthma and allergic diseases, will be examined in this trial with the help of the Airways Clinical Research Centers (ACRC).
• In April 2026, fixed-dose triple-combination therapy BREZTRI Aerosphere®â€¯(budesonide/glycopyrrolate/formoterol fumarate), which is a single-inhaler combining the efficacy of corticosteroid/long-acting beta2-agonist with a long-acting muscarinic antagonist, was approved in the US for the maintenance treatment of asthma in adult and pediatric patients. In 2020, it was approved for the treatment of chronic obstructive pulmonary disease (COPD) in adults.

Market Value Chain

R&D

• The R&D of the North America asthma and COPD drugs focuses on the development of targeted biologics, long-acting injectables, and anti-inflammatory rescue therapies.
• Key players: GlaxoSmithKline, Regeneron Pharmaceuticals, Sanofi.

Clinical Trials and Regulatory Approvals

• The drug efficacy, device performance, manufacturing quality, and patient safety are evaluated in the clinical trials and regulatory approvals of the asthma and COPD drugs in North America.
• Key players: GlaxoSmithKline, Regeneron Pharmaceuticals, Sanofi.

Patient Support and Services

• The financial aid, nurse training, and copay cards are provided in the patient support and services of the asthma and COPD drugs in North America.
• Key players: GlaxoSmithKline, Regeneron Pharmaceuticals, Sanofi.

Market Growth

The North America asthma and COPD drugs market size was estimated at USD 16.38 billion in 2025 and is predicted to increase from USD 17.13 billion in 2026 to approximately USD 25.68 billion by 2035, expanding at a CAGR of 4.6% from 2026 to 2035.